JCAHO Accredited
Call Us 800-444-1838
In March 2019, the U.S. Food and Drug Administration (FDA) announced the approval of Spravato (Esketamine) for use in patients diagnosed with treatment-resistant depression. Spravato is a nasal spray that can only be administered by an approved health care provider, in the physician’s office or clinic, because the main ingredient is a chemical relative of […]
“Magic Mushrooms,” an organic species of hallucinogenic-fungi containing psilocybin as the main psychoactive ingredient, are making headway into mainstream medical research. In late 2018 The Food and Drug Administration (FDA) granted “breakthrough therapy” designation to a study into psilocybin therapy for treatment-resistant depression (TRD). “Psilocybin may be giving [patients] the temporary ‘kick start’ they need […]
Before psychedelic drugs like psilocybin mushrooms, peyote, mescaline and LSD were outlawed in the United States, scientists studied the potential medicinal effects of these substances with great interest. After the Controlled Substances Act of 1970 classified a number of psychedelics as Schedule I narcotics, funding for this kind of research all but disappeared, until recently. […]
